Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation
Authors:
- Evangelos Eleutherakis PapaiakovouEPEvangelos Eleutherakis Papaiakovou
- Vasiliki SpiliopoulouVSVasiliki Spiliopoulou
- 1 September 2023
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 64 (13) , 2140-2147
Abstract
Autologous stem cell transplantation (ASCT) remains a standard therapy for multiple myeloma (MM) patients. Our study aimed to assess the impact of daratumumab-containing induction on stem cell (SC) mobilization, apheresis and hospitalization. We evaluated 200 newly diagnosed MM patients that were mobilized for SC collection and which received induction with (N = 40) or without daratumumab (N = 160). Dara group patients required more frequent use of plerixafor, larger collection volumes, and had lower SC yield. 87.5% (35/40) of dara group patients achieved the planned yield of ≥ 5 × 10^6 CD34+/kg for at least one transplant compared to 96.2% (154/160) of patients in the non-dara group. Dara group patients had delayed hematopoietic recovery (11 vs 10 days for PMN > 0.5 × 10E9/l), required more transfusions (4 vs 2 plts), prolonged hospitalization (20 vs 18 days), more febrile episodes and prolonged antibiotic administration. Despite daratumumab effect patients finally achieved a successful stem cell collection and proceeded to transplant.Keywords
This publication has 35 references indexed in Scilit:
- Multiple myelomaThe Lancet, 2015
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Specific Autoantibody Production in Primary Thymic Cell Cultures from Early-Onset Myasthenia Gravis PatientsThe Journal of Immunology, 2014
- Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple MyelomaJournal of Clinical Oncology, 2013
- Implications of continued response after autologous stem cell transplantation for multiple myelomaBlood, 2013
- Multiple MyelomaNew England Journal of Medicine, 2011
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsThe Journal of Immunology, 2011
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyThe Lancet, 2010
- Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody ProductionAmerican Journal of Transplantation, 2008
- Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokinesBlood, 2006